Arcus biosciences reports fourth quarter and full year 2020 financial results and provides operational highlights

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results for the fourth quarter and year ended december 31, 2020 and provided operational highlights. “with $735 million in cash at the end of the year, plus $220 million from gilead's recent equity investment, we are extremely well-positioned to accelerate the advancement of our pipeline, initiate our firs
RCUS Ratings Summary
RCUS Quant Ranking